Company Search:
Advanced Search
Sponsored Links
Epigenomics AG Company Snapshot
Epigenomics AG operates in the Diagnostic substances sector. In addition to historical fundamental analyses, the complete report available to purchase compares Epigenomics AG with three other pharmaceutical manufacturers in Europe: Paion AG (2016 sales of 4.26 million Euro [US$5.19 million] of which 100% was Pharmaceutical), Erytech Pharma SA of France (4.14 million Euro [US$5.04 million] of which 100% was Pharmacy), and Onxeo SA which is also based in France (4.42 million Euro [US$5.39 million] of which 82% was Operating segment -Rest of the world).

Sales Analysis. Epigenomics AG reported sales of 4.20 million Euro (US$5.12 million) for the year ending December of 2016. This represents an increase of 101.8% versus 2015, when the company's sales were 2.08 million Euro. Sales of Licenses saw an increase that was more than double the company's growth rate: sales were up 261.5% in 2016, from 156,000.00 Euro to 564,000.00 Euro. Not all segments of Epigenomics AG experienced an increase in sales in 2016: sales of Research and Development fell 79.5% to 74,000.00 Euro.
Company ReportsSubscriptions
Looking For More?
Purchace an In-Depth Report
Epigenomics AG
  Stock Performance Chart for Epigenomics AG
  Stock Data: Recent Stock Performance:
  Current Price (1/19/2018): 4.54
(Figures in Euro)
1 Week 2.5%   13 Weeks 12.5%  
4 Weeks -1.0%   52 Weeks -2.4%  
Epigenomics AG Key Data:
  Ticker: ECX Country: Germany
  Exchanges: FRA Major Industry: Pharmaceuticals & Biotechnology
    Sub Industry: Diagnostic Substances
  2016 Sales 4,201,000
(Year Ending Jan 2017).
Employees: 45
  Currency: Euro Market Cap: 103,218,080
  Fiscal Yr Ends: December Shares Outstanding: 22,735,260
  Share Type: STAMMAKTIE Closely Held Shares: 6,512,693
Sponsored Links
Feedback | Terms and Conditions | Privacy Policy | Site Index
CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.